Elekta AB (publ) (OTCMKTS:EKTAY – Get Free Report) and BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, valuation, profitability, analyst recommendations, earnings and dividends.
Insider and Institutional Ownership
18.9% of BioNexus Gene Lab shares are held by institutional investors. 41.3% of Elekta AB (publ) shares are held by insiders. Comparatively, 6.8% of BioNexus Gene Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Elekta AB (publ) and BioNexus Gene Lab, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Elekta AB (publ) | 2 | 0 | 0 | 0 | 1.00 |
BioNexus Gene Lab | 0 | 0 | 0 | 0 | N/A |
Earnings & Valuation
This table compares Elekta AB (publ) and BioNexus Gene Lab’s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Elekta AB (publ) | $1.61 billion | 1.71 | $90.25 million | $0.36 | 20.03 |
BioNexus Gene Lab | $9.77 million | 1.13 | -$2.63 million | ($0.02) | -31.00 |
Elekta AB (publ) has higher revenue and earnings than BioNexus Gene Lab. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Elekta AB (publ), indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Elekta AB (publ) and BioNexus Gene Lab’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Elekta AB (publ) | 7.88% | 15.16% | 5.01% |
BioNexus Gene Lab | -26.90% | -32.99% | -26.99% |
Summary
Elekta AB (publ) beats BioNexus Gene Lab on 9 of the 10 factors compared between the two stocks.
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
About BioNexus Gene Lab
BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Receive News & Ratings for Elekta AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.